J Gynecol Oncol.
2024 Mar;35(2):e44. 10.3802/jgo.2024.35.e44.
Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines
- Yoo JG
1 - Lee SJ2
- Nam EJ3
- No JH4
- Park JY5
- Song JY6
- Shin SJ7
- Yun BS8
- Park ST9
- Lee SH10
- Suh DH4
- Kim YB4
- Lee TS11
- Bae JM12
- Lee KH2
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon, Korea
- 2Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
- 3Department of Obstetrics and Gynecology, Institute of Women’s Medical Life Science, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- 4Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea
- 5Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
- 6Department of Obstetrics and Gynecology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
- 7Department of Obstetrics and Gynecology, Keimyung University Dongsan Medical Center, Daegu, Korea
- 8Department of Obstetrics and Gynecology, CHA Ilsan Medical Center, CHA University, Goyang, Korea
- 9Department of Obstetrics and Gynecology, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea
- 10Department of Obstetrics and Gynecology, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Wonju, Korea
- 11Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
- 12Department of Obstetrics and Gynecology, Hanyang University Medical Center, Seoul, Korea
- KMID: 2564882
- DOI: http://doi.org/10.3802/jgo.2024.35.e44
Abstract
- This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelines for the management of cervical cancer incorporates recent research findings and changes in treatment strategies based on version 4.0 released in 2020. Each key question was developed by focusing on recent notable insights and crucial contemporary issues in the field of cervical cancer. These questions were evaluated for their significance and impact on the current treatment and were finalized through voting by the development committee. The selected key questions were as follows: the efficacy and safety of immune checkpoint inhibitors as firstor second-line treatment for recurrent or metastatic cervical cancer; the oncologic safety of minimally invasive radical hysterectomy in early stage cervical cancer; the efficacy and safety of adjuvant systemic treatment after concurrent chemoradiotherapy in locally advanced cervical cancer; and the oncologic safety of sentinel lymph node mapping compared to pelvic lymph node dissection. The recommendations, directions, and strengths of this guideline were based on systematic reviews and meta-analyses, and were finally confirmed through public hearings and external reviews. In this study, we describe the revised practice guidelines for the management of cervical cancer.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines
- Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines
- Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines
- Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment
- Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines
